<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-156491" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>DaxibotulinumtoxinA-Ianm</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dodia</surname>
            <given-names>Paarth</given-names>
          </name>
          <aff>Campbell University/Sampson Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rice</surname>
            <given-names>Ashley S.</given-names>
          </name>
          <aff>CUSOM/Sampson Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Paarth Dodia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashley Rice declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-156491.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">DaxibotulinumtoxinA is a medication belonging to the neurotoxin class and is utilized to manage and treat moderate-to-severe glabellar lines associated with corrugator or procerus muscle activity in adult patients. This activity provides an overview of the indications, contraindications, and pharmacology for daxibotulinumtoxinA as an agent in the cosmetic management of rhytides. This activity&#x000a0;reviews the adverse event profile, off-label uses, dosing, monitoring recommendations, and relevant interactions of this medication to enhance the competence of interprofessional healthcare team members when caring for patients with glabellar lines.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients that meet the criteria for daxibotulinumtoxinA treatment based on their aesthetic concerns and medical history.</p></list-item><list-item><p>Screen patients for any adverse events or complications following daxibotulinumtoxinA administration.</p></list-item><list-item><p>Apply appropriate dosage and treatment plans tailored to individual patient's needs and desired outcomes using comprehensive clinical expertise.</p></list-item><list-item><p>Communicate effectively with patients by providing clear information about the procedure, expected outcomes, and potential risks of the daxibotulinumtoxinA treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=156491&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=156491">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-156491.s2" sec-type="Indications">
        <title>Indications</title>
        <p>DaxibotulinumtoxinA belongs to the same class of potent neurotoxins as onabotulinumtoxinA and abobotulinumtoxinA, which are toxins derived from the <italic toggle="yes">Clostridium botulinum&#x000a0;</italic>bacteria.<xref ref-type="bibr" rid="article-156491.r1">[1]</xref><xref ref-type="bibr" rid="article-156491.r2">[2]</xref>&#x000a0;</p>
        <p><italic toggle="yes">C botulinum</italic> is a gram-positive, rod-shaped, spore-forming bacterium&#x000a0;primarily present in soil.<xref ref-type="bibr" rid="article-156491.r3">[3]</xref> This anaerobic bacterium is known for producing toxins that can cause botulism in humans. Botulism is a toxidrome that presents with symmetrical, acute, descending, flaccid paralysis in individuals, resulting from the loss of voluntary motor muscle use due to cholinergic blockade at the synaptic cleft. Botulism is commonly transmitted through the consumption of home-canned food or traditional local foods.<xref ref-type="bibr" rid="article-156491.r4">[4]</xref>&#x000a0;</p>
        <p>The same toxin has been linked to infantile botulism, which is associated with the consumption of honey due to the persistence of spores in it.<xref ref-type="bibr" rid="article-156491.r5">[5]</xref> DaxibotulinumtoxinA is specifically derived from the Hall strain of <italic toggle="yes">C botulinum</italic>. The therapeutic application of this toxin can significantly alleviate problems arising from cholinergic signaling.&#x000a0;</p>
        <p>
<bold>FDA-Approved Indication</bold>
</p>
        <p>DaxibotulinumtoxinA is approved by the U.S. Food and Drug Administration (FDA) for temporary improvement in the appearance of moderate-to-severe glabellar lines in adult patients associated with corrugator or procerus muscle activity.<xref ref-type="bibr" rid="article-156491.r6">[6]</xref></p>
        <p>Although this injectable medication shares a similar mechanism of action and effects with other botulinum toxins, its FDA approval is limited to the abovementioned indication. Other botulinum toxins are used to treat conditions such as hyperhidrosis, urinary incontinence, cervical dystonia, trigeminal neuralgia, and various types of neuropathic pain.</p>
        <p>The phase 3 trials for daxibotulinumtoxinA, known as SAKURA-1 and SAKURA-2, were conducted as multicenter, randomized, parallel-group,&#x000a0;double-blind trials. These trials consisted of 36-week pivotal trials followed by 84-week open-label trials with repeated dosing. The specific focus of the studies was on patients with moderate-to-severe glabellar lines. The results of these trials indicated that the most significant advantage&#x000a0;of daxibotulinumtoxinA is its ability to provide a "more prolonged clinical benefit"&#x000a0;compared to&#x000a0;the preexisting botulinum&#x000a0;toxins on the market.<xref ref-type="bibr" rid="article-156491.r7">[7]</xref> This extended duration of effect of the medication potentially reduces the frequency of injections required per year while maintaining the same cosmetic benefit.</p>
      </sec>
      <sec id="article-156491.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The daxibotulinumtoxinA molecule shares a similar mechanism of action with other neurotoxins derived from <italic toggle="yes">C botulinum</italic>. As a class, these neurotoxins function by binding to glycoprotein structures present on cholinergic presynaptic nerve terminals. This binding capability allows them to disrupt the release of acetylcholine.<xref ref-type="bibr" rid="article-156491.r8">[8]</xref>&#x000a0;</p>
        <p>The interruption of neurotransmitter release is achieved through the cleavage of SNAP25, a soluble <italic toggle="yes">N</italic>-ethylmaleimide-sensitive factor attachment receptor protein. The SNAP25 protein facilitates the docking and release of synaptic vesicle membrane contents, such as acetylcholine, particularly in skeletal muscle. Although&#x000a0;this inhibition is reversible, as the duration of the medication's action decreases, there is a subsequent reduction in neurotransmitter release at the neuromuscular junction. This, in turn, leads to a decrease in muscular contraction near the injection sites.</p>
        <p>The inhibition of skeletal muscle contraction is observed as a response that depends on the dosage administered. Similar to other botulinum toxins, the degradation of the neurotoxin and the formation of new axonal sprouts facilitate the return of muscle innervation and subsequent activity.</p>
        <p>DaxibotulinumtoxinA differentiates itself from other botulinum neurotoxins primarily due to its smaller size and the utilization of a proprietary excipient protein. The molecular weight of daxibotulinumtoxinA is 150 kDa, which is similar to incobotulinumtoxinA but smaller than other botulinum neurotoxins currently available in the US market. Furthermore, other botulinum neurotoxins are bound to human serum albumin through the excipient peptide.</p>
        <p>DaxibotulinumtoxinA utilizes a unique stabilizing excipient peptide called RTP004, which is proprietary to its formulation. Due to its high positive charge, the synthetic RTP004 forms an electrostatic bond with daxibotulinumtoxinA. This positive charge also facilitates the binding of daxibotulinumtoxinA to other negatively charged structures, including the extracellular matrix proteins present on the neuronal surface.</p>
        <p>In vitro studies have demonstrated that the enhanced binding facilitated by the electrostatic charges contributes to reduced diffusion of the neurotoxin, potentially resulting in a longer duration of drug effect. Furthermore, the RTP004 excipient peptide also prevents the adsorption of daxibotulinumtoxinA to container surfaces, which is a specific function that is also fulfilled by human serum albumin.<xref ref-type="bibr" rid="article-156491.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Absorption: Botulinum toxins are primarily absorbed at the injection site. The uptake rate of botulinum toxins can be influenced by local activity and temperature, leading to an augmented absorption process.<xref ref-type="bibr" rid="article-156491.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Distribution: Some local distribution of botulinum toxins can occur through the connective tissue near the injection site. Therefore, it is advised to avoid changing position too soon after administering the injection as it can worsen the distribution of the toxin. To ensure optimal results, it is recommended not to lie down for at least 4 hours after administering the injection. Although&#x000a0;botulinum toxins can be distributed through the bloodstream due to their stability, they do not accumulate in organs. Their primary target is cholinergic nerve endings.<xref ref-type="bibr" rid="article-156491.r10">[10]</xref> According to the FDA package insert, daxibotulinumtoxinA is not detectable in the bloodstream when administered at the recommended dose.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Metabolism: The mechanisms of metabolism and excretion at therapeutic doses have not been thoroughly investigated. However, theories have emerged from studies conducted using multiple lethal doses. Circulating proteases might contribute to the degradation of the active toxin, or the toxin itself may dislodge and be transported via the bloodstream to the liver for cleavage and conjugation.<xref ref-type="bibr" rid="article-156491.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Excretion: The theory of hepatic biotransformation holds merit as the excretion of most molecules through renal filtration requires molecular sizes smaller than approximately 50 kDa. As the active component of the daxibotulinumtoxinA molecule is 150 kDa, it would require some form of cleavage before renal filtration becomes plausible.<xref ref-type="bibr" rid="article-156491.r10">[10]</xref>&#x000a0;However, additional studies are required to precisely determine the mechanism of metabolism and excretion for all botulinum toxins.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-156491.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>DaxibotulinumtoxinA is supplied in a powder form&#x000a0;that can be reconstituted and administered through intramuscular injection into the corrugator and procerus muscles for the relaxation of glabellar lines as recommended by the FDA. The activity will be similar in any other skeletal muscle.</p>
        <p>
<bold>Strength</bold>
</p>
        <p>DaxibotulinumtoxinA is available in 50- and 100-unit vials as a powder form, which requires reconstitution with sterile 0.9% sodium chloride solution at a ratio of 8 units per 0.1 mL. For the 50-unit vial, it is advised to inject 0.6 mL per vial. Similarly, for the 100-unit vial, the recommended injection volume is 1.2 mL per vial.</p>
        <p>
<bold>Adult Dose</bold>
</p>
        <p>Per the package insert, the recommended dose for glabellar lines&#x000a0;is 40 units of daxibotulinumtoxinA. Units of measurement for botulinum toxins are not convertible among different formulations.&#x000a0;</p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatic impairment: No dosage adjustment is recommended for patients with hepatic impairment.</p>
          </list-item>
          <list-item>
            <p>Renal impairment: No dosage adjustment is recommended for patients with renal impairment.</p>
          </list-item>
          <list-item>
            <p>Pregnant patients: The use of daxibotulinumtoxinA in pregnant patients through injections has not been studied. However, botulinum toxins are generally contraindicated during pregnancy. Animal studies have shown adverse effects on fetal growth. Still, these effects were observed at maternally toxic doses and much higher than the maximum recommended human dose (approximately 40 times higher).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Breastfeeding mothers: There is currently no available data regarding the presence of daxibotulinumtoxinA in human or animal milk, its effects on breastfed infants, or its impact on milk supply.</p>
          </list-item>
          <list-item>
            <p>Pediatric patients: Studies have not been conducted on patients younger than 18, and the safety and effectiveness of daxibotulinumtoxinA in this population have not been established.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Older patients: No dosage adjustment is recommended for older patients.</p>
          </list-item>
        </list>
        <p>The reconstituted daxibotulinumtoxinA must be administered via injection within 72 hours of its preparation. During this time, storing the product&#x000a0;in a refrigerator at a temperature range of&#x000a0;6&#x000a0;to 8 &#x000b0;C is essential. After reconstitution, the prepared daxibotulinumtoxinA should be used for a single patient in a single session. Any unused reconstituted daxibotulinumtoxinA must be discarded and not used for any other purpose.<xref ref-type="bibr" rid="article-156491.r11">[11]</xref></p>
        <p>Before administering&#x000a0;any botulinum toxin product, it is essential to assess the areas to be treated in static and dynamic states, identify and discuss the patient's goals, and note any preexisting asymmetry. Following the injection, advise the patient to refrain from lying down or manipulating the tissue around the treated area.</p>
        <p>Treatments should be scheduled with a minimum interval of 3 months between sessions. In some patients, the efficacy of repeated treatments with other botulinum toxins has been observed to decline over time. This reduction in effectiveness can be attributed to immunogenicity, which refers to the body's ability to develop an immune response and produce neutralizing antibodies against the toxin. During the SAKURA trials, no evidence of immunogenicity was observed within the designated time frame, although it is a common clinical concern encountered with many biological medications.<xref ref-type="bibr" rid="article-156491.r12">[12]</xref></p>
      </sec>
      <sec id="article-156491.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Drug Reactions</bold>
</p>
        <p>Various adverse effects&#x000a0;may arise due to the&#x000a0;infiltration of the neurotoxin into muscles beyond the intended target. However, proper neurotoxin administration without adjacent infiltration minimizes adverse effects, such as unintended injury.&#x000a0;The phase 3 trials for daxibotulinumtoxinA reported a headache as the most common adverse effect, with rates of 7% in SAKURA-1 and 5.9% in SAKURA-2.<xref ref-type="bibr" rid="article-156491.r7">[7]</xref>&#x000a0;</p>
        <p>As with other botulinum toxin injections, the effect of daxibotulinumtoxinA might extend beyond the initial injection site if the solution migrates beneath the skin's surface. Consequently, the disruption of local cholinergic signaling will occur wherever the neurotoxin spreads, resulting in various adverse effects specific to each region. These effects encompass, but are not restricted to, generalized muscle weakness, ptosis, diplopia, dysphagia, dysarthria, and breathing difficulties. The same adverse effects can manifest when the medication is mistakenly injected into incorrect areas.</p>
        <p>The severity of these symptoms will depend on the injected dose of the medication. Although symptoms have been reported to occur as early as a few hours after injection, they typically take weeks to manifest due to the medication's mechanism of action, which often requires several weeks to develop fully.</p>
        <p>Although daxibotulinumtoxinA lacks FDA approval for spasticity treatment, alternative botulinum toxins used for spasticity treatment have exhibited more severe, life-threatening effects,&#x000a0;including dysphagia and breathing difficulties. However, such complications have not been reported with daxibotulinumtoxinA injections targeting the glabella. Nevertheless, the injection process may result in commonly observed issues associated with other injections, such as bruising, erythema, and pain at and around the injection site.<xref ref-type="bibr" rid="article-156491.r13">[13]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Botulinum toxin effects can be potentiated if administered to patients taking aminoglycoside antibiotics or anticholinergic agents. DaxibotulinumtoxinA should be administered with close observation after weighing and discussing risks and benefits.&#x000a0;</p>
      </sec>
      <sec id="article-156491.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Absolute contraindications to botulinum toxins include hypersensitivity reactions or an active infection at the injection site.<xref ref-type="bibr" rid="article-156491.r14">[14]</xref><xref ref-type="bibr" rid="article-156491.r15">[15]</xref>&#x000a0;The hypersensitivity symptoms can range from tissue edema and urticaria to anaphylaxis.</p>
        <p>
<bold>Precautions</bold>
</p>
        <p>Relative contraindications are broad and recommended, but there has been some recent discussion in the literature as to whether all of these recommendations are warranted; however, they will be reviewed here.<xref ref-type="bibr" rid="article-156491.r16">[16]</xref></p>
        <p>Botulinum toxins are not recommended in patients with preexisting neuromuscular disorders, such as myasthenia gravis, due to the potential to worsen the preexisting neuromuscular compromise. Botulinum toxins should be used cautiously in patients with preexisting cardiovascular disease due to reports of arrhythmias triggered by botulinum toxin injections.&#x000a0;</p>
        <p>No current&#x000a0;data exists regarding&#x000a0;risks in&#x000a0;specific patient populations, such as pregnant, lactating, and pediatric patients. The clinical&#x000a0;trials did not include a sufficiently large enough group of patients over age&#x000a0;65 to ascertain whether there was a variation in response in older patients.&#x000a0;</p>
      </sec>
      <sec id="article-156491.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Most botulinum toxins available on the market for relaxing rhytides tend to be efficacious for a period of 3 to 4 months on average.<xref ref-type="bibr" rid="article-156491.r8">[8]</xref>&#x000a0;However, the clinical trials of daxibotulinumtoxinA provide evidence supporting that the median duration of the medication is 24 weeks or 6 months.<xref ref-type="bibr" rid="article-156491.r17">[17]</xref>&#x000a0;</p>
        <p>At present, comparative trials have not yet been conducted. In general, with neurotoxin injections, patients are recommended to return for a follow-up visit at least 2 weeks after the injection has been administered to them to assess the treatment's efficacy and evaluate facial symmetry.&#x000a0;During this visit, the patient should also be assessed for any migration of the neurotoxin and monitored for the previously mentioned adverse effects.&#x000a0;</p>
      </sec>
      <sec id="article-156491.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Although the LD50 for daxibotulinumtoxinA has not been directly established in humans, animal testing conducted during the trials indicated that a dosage of 2.4 units/kg/d proved lethal in rabbits. In the case of botulinum toxins, it has previously been estimated that the human LD50 falls within the range of 1 to 3 ng/kg.<xref ref-type="bibr" rid="article-156491.r18">[18]</xref>&#x000a0;</p>
        <p>Migration of the toxin is a prerequisite for symptoms of overdose, which can result in a range of paralyzing effects determined by the specific muscles affected. Possible manifestations include ptosis, dysphagia, dysphonia, urinary incontinence, and other related symptoms. However, the foremost concern in such a scenario is the potential development of respiratory distress.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>In&#x000a0;cases of&#x000a0;an overdose,&#x000a0;the patient should be promptly admitted to a hospital for close medical supervision. The attending physician should also initiate communication with the local or state health department to procure an antitoxin from The Centers for Disease Control and Prevention (CDC). If respiratory distress is observed, active respiratory support, such as ventilation, should be administered to the patient immediately to ensure their well-being.</p>
        <p>Although a specific antidote for daxibotulinumtoxinA has not been identified yet, an equine-derived antitoxin is available for botulinum toxin, which can help mitigate any additional effects of the botulinum toxin. However, the antitoxin cannot reverse the effects of already bound toxins, as it does not actively reverse the de-innervation of musculature.<xref ref-type="bibr" rid="article-156491.r4">[4]</xref>&#x000a0;In addition, approximately 1 in 10 individuals who receive the antitoxin may experience a hypersensitivity reaction.<xref ref-type="bibr" rid="article-156491.r11">[11]</xref></p>
      </sec>
      <sec id="article-156491.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing cosmetic injection medications requires an interprofessional team of healthcare professionals comprising clinicians and pharmacists. Effectively caring for these patients entails extensive communication to comprehend their treatment objectives and assist them in establishing realistic expectations regarding the therapeutic options utilized.&#x000a0;</p>
        <p>All healthcare team members should feel comfortable&#x000a0;educating and counseling patients regarding the timing of medication onset and the duration of its action. During this discussion, it is essential to highlight that the medication's effects are not permanent; therefore, subsequent re-injections will be necessary to maintain efficacy. Furthermore, a thorough assessment of the patient's medical history should be conducted to identify any absolute or relative contraindications. In addition, an open conversation should take place to address both the risks and benefits associated with daxibotulinumtoxinA.</p>
        <p>All healthcare team members should be aware of the appropriate&#x000a0;course of action&#x000a0;in case of a suspected overdose or toxicity. Adopting a collaborative approach with open lines of communication within the team will help ensure optimal cosmetic outcomes when using daxibotulinumtoxinA while minimizing potential adverse events.</p>
      </sec>
      <sec id="article-156491.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=156491&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=156491">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/156491/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=156491">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-156491.s11">
        <title>References</title>
        <ref id="article-156491.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solish</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Carruthers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>81</volume>
            <issue>18</issue>
            <fpage>2091</fpage>
            <page-range>2091-2101</page-range>
            <pub-id pub-id-type="pmid">34787840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dressler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saberi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin: mechanisms of action.</article-title>
            <source>Arq Neuropsiquiatr</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>180</fpage>
            <page-range>180-5</page-range>
            <pub-id pub-id-type="pmid">15830090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nigam</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Nigam</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin.</article-title>
            <source>Indian J Dermatol</source>
            <year>2010</year>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">20418969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lonati</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schicchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crevani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buscaglia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scaravaggi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cirronis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petrolini</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Foodborne Botulism: Clinical Diagnosis and Medical Treatment.</article-title>
            <source>Toxins (Basel)</source>
            <year>2020</year>
            <month>Aug</month>
            <day>07</day>
            <volume>12</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">32784744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanzi</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Gabay</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Association between honey consumption and infant botulism.</article-title>
            <source>Pharmacotherapy</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>1479</fpage>
            <page-range>1479-83</page-range>
            <pub-id pub-id-type="pmid">12432974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mussarat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Azam</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Nafees Uddin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Nasrullah</surname>
                <given-names>RMU</given-names>
              </name>
              <name>
                <surname>Siddiq</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>DAXI (DaxibotulinumtoxinA) - An Innovative Approach for Frown Lines.</article-title>
            <source>Int J Gen Med</source>
            <year>2023</year>
            <volume>16</volume>
            <fpage>1267</fpage>
            <page-range>1267-1269</page-range>
            <pub-id pub-id-type="pmid">37065981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carruthers</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Fagien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Biesman</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>RG</given-names>
              </name>
              <collab>SAKURA 1 and SAKURA 2 Investigator Group</collab>
              <collab>SAKURA 1 and SAKURA 2 Investigator Group includes the following</collab>
            </person-group>
            <article-title>DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).</article-title>
            <source>Plast Reconstr Surg</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>145</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-58</page-range>
            <pub-id pub-id-type="pmid">31609882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Dayan</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Comparison and overview of currently available neurotoxins.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>31</fpage>
            <page-range>31-9</page-range>
            <pub-id pub-id-type="pmid">24587850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them.</article-title>
            <source>Toxicon</source>
            <year>2015</year>
            <month>Dec</month>
            <day>01</day>
            <volume>107</volume>
            <issue>Pt A</issue>
            <fpage>64</fpage>
            <page-range>64-7</page-range>
            <pub-id pub-id-type="pmid">26220801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The life history of a botulinum toxin molecule.</article-title>
            <source>Toxicon</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>68</volume>
            <fpage>40</fpage>
            <page-range>40-59</page-range>
            <pub-id pub-id-type="pmid">23518040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhaked</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin: bioweapon &#x00026; magic drug.</article-title>
            <source>Indian J Med Res</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>132</volume>
            <issue>5</issue>
            <fpage>489</fpage>
            <page-range>489-503</page-range>
            <pub-id pub-id-type="pmid">21149997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carr</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sublett</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications.</article-title>
            <source>Adv Ther</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>5046</fpage>
            <page-range>5046-5064</page-range>
            <pub-id pub-id-type="pmid">34515975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galadari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kroumpouzos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Katsambas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lotti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vojvodic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grabbe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Juchems</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goldust</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Complications of botulinum toxin and fillers: A narrative review.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>570</fpage>
            <page-range>570-573</page-range>
            <pub-id pub-id-type="pmid">31889407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Contraindications and complications with the use of botulinum toxin.</article-title>
            <source>Clin Dermatol</source>
            <year>2004</year>
            <season>Jan-Feb</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-75</page-range>
            <pub-id pub-id-type="pmid">15158548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Thompkins</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">26879873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ran</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Is myasthenia gravis a contraindication for botulinum toxin?</article-title>
            <source>J Clin Neurosci</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>95</volume>
            <fpage>44</fpage>
            <page-range>44-47</page-range>
            <pub-id pub-id-type="pmid">34929650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabi</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Dhawan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kontis</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study.</article-title>
            <source>Dermatol Surg</source>
            <year>2021</year>
            <month>Jan</month>
            <day>01</day>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-54</page-range>
            <pub-id pub-id-type="pmid">32773446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156491.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horowitz</surname>
                <given-names>BZ</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin.</article-title>
            <source>Crit Care Clin</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>825</fpage>
            <page-range>825-39, viii</page-range>
            <pub-id pub-id-type="pmid">16168317</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
